Beckmann Nicolau, Laurent Didier, Tigani Bruno, Panizzutti Rogério, Rudin Markus
Novartis Institutes for BioMedical Research, Discovery Technologies, Analytics and Imaging Sciences Unit, Lichstr. 35, WSJ-386.209, CH-4002 Basel Switzerland.
Drug Discov Today. 2004 Jan 1;9(1):35-42. doi: 10.1016/S1359-6446(04)02943-5.
Imaging technologies are presently receiving considerable attention in the pharmaceutical area owing to their potential to accelerate the drug discovery and development process. One of the principal imaging modalities is magnetic resonance imaging (MRI). The multiparametric nature of MRI enables anatomical, functional and even molecular information to be obtained non-invasively from intact organisms at high spatial resolution, thereby enabling a comprehensive characterization of a disease state and the corresponding drug intervention. The non-invasiveness of MRI strengthens the link between pre-clinical and clinical drug studies, making the technique attractive for pharmaceutical research.